Avalo Therapeutics, Inc. (AVTX) stock
AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.70−0.43 (-6.03%)
Close on Nov 18, 2026Market cap $359.32MP/E –Yield –
Avalo Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Avalo Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$91.36M. For fiscal 2025 it was -$72.93M. The highest annual figure on record is $13.89M in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$72.93M | – |
| FY2024 | Dec 31, 2024 | -$68.51M | – |
| FY2023 | Dec 31, 2023 | -$27.35M | – |
| FY2022 | Dec 31, 2022 | -$37.44M | – |
| FY2021 | Dec 31, 2021 | -$82.13M | – |
| FY2020 | Dec 31, 2020 | -$72.84M | – |
| FY2019 | Dec 31, 2019 | -$16.14M | – |
| FY2018 | Dec 31, 2018 | -$35.38M | -354.7% |
| FY2017 | Dec 31, 2017 | $13.89M | – |
| FY2016 | Dec 31, 2016 | -$16.08M | – |
| FY2015 | Dec 31, 2015 | -$11.01M | – |
| FY2014 | Dec 31, 2014 | -$17.12M | – |
| FY2013 | Dec 31, 2013 | -$12.93M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$31.52M | – |
| Q1 FY2026 | Mar 31, 2026 | -$20.90M | – |
| Q4 FY2025 | Dec 31, 2025 | -$19.74M | – |
| Q3 FY2025 | Sep 30, 2025 | -$19.20M | – |
| Q2 FY2025 | Jun 30, 2025 | -$19.32M | – |
| Q1 FY2025 | Mar 31, 2025 | -$14.67M | – |
| Q4 FY2024 | Dec 31, 2024 | -$13.31M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.86M | – |
| Q2 FY2024 | Jun 30, 2024 | -$9.58M | – |
| Q1 FY2024 | Mar 31, 2024 | -$32.77M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.66M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.75M | -191.6% |
| Q2 FY2023 | Jun 30, 2023 | -$7.15M | – |
| Q1 FY2023 | Mar 31, 2023 | -$8.79M | – |
| Q4 FY2022 | Dec 31, 2022 | -$8.86M | – |
| Q3 FY2022 | Sep 30, 2022 | $4.10M | – |
| Q2 FY2022 | Jun 30, 2022 | -$11.83M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.85M | – |
| Q4 FY2021 | Dec 31, 2021 | -$17.96M | – |
| Q3 FY2021 | Sep 30, 2021 | -$16.46M | – |
| Q2 FY2021 | Jun 30, 2021 | -$17.13M | – |
| Q1 FY2021 | Mar 31, 2021 | -$30.58M | – |
| Q4 FY2020 | Dec 31, 2020 | -$16.34M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.28M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.82M | – |
| Q1 FY2020 | Mar 31, 2020 | -$31.41M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.72M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.86M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.55M | – |
| Q1 FY2019 | Mar 31, 2019 | -$5.00M | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.56M | – |
| Q3 FY2018 | Sep 30, 2018 | -$24.31M | -210.9% |
| Q2 FY2018 | Jun 30, 2018 | -$5.75M | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.75M | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.36M | – |
| Q3 FY2017 | Sep 30, 2017 | $21.92M | – |
| Q2 FY2017 | Jun 30, 2017 | -$1.77M | – |
| Q1 FY2017 | Mar 31, 2017 | -$1.90M | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.69M | – |
| Q3 FY2016 | Sep 30, 2016 | -$5.96M | – |
See a number that looks wrong?